ViroCyt Raises $3.5M for Virus Quantification technology
ViroCyt, a existence sciences startup primarily based in Boulder, CO, lately raised $ 3.5 million to proceed advertising and marketing lab equipment that scientists can use to decide the quantity of virus particles (equivalent to Ebola) that is existing in a blood or tissue pattern.
according to SEC filings, ViroCyt has raised $ 11.7 million since it used to be fashioned in 2012.
An example of just how helpful the expertise may also be passed off remaining summer season from researchers trying to enhance vaccines and treatments for Ebola. a gaggle known as the Filovirus Animal Nonclinical staff, or FANG, used the counter to resolve the quantity of the virus in a pattern and assist pace up their work. FANG is a consortium of yank, British, and Canadian scientists that’s led by way of the departments of safety and health and Human services. in addition to Ebola, FANG researches the Marburg virus, which is within the viral family as Ebola and also causes deadly hemorrhagic fever.
the corporate says its instrument, the Virus Counter, can provide results in minutes, besting traditional the way to quantify viruses that can take days or even weeks.
ViroCyt previously was part of any other Boulder existence science firm, InDevR, which at the start developed the know-how. ViroCyt was once spun out of InDevR in late 2012 so it might center of attention on commercialization while InDevR continued to focal point on developing new instruments, arrays, and assays that can be used for genotyping and creating vaccines.
InDevR final 12 months bought a $ 2.9 million grant from the national Institute of allergic reaction and Infectious illnesses for a package that can take a look at the efficiency of vaccines for pandemic influenza. the company additionally signed a contract with the Biomedical evolved analysis and construction Authority that may be value up to $ 14.7 million for technology that can impulsively genotype influenza viruses.
(120)
